Pluristem Chairman and CEO, Mr. Zami Aberman commented, "These preliminary results are encouraging. We intend to pursue further in vitro and in vivo studies with our PLX cells in the treatment of Parkinson's Disease as well as other disorders of the central nervous system. As a cellular therapy for PD and other neurodegenerative diseases, our PLX cells could be a readily available source of important enzymes, neurotransmitters and neurotrophic factors." Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
The in vitro assay demonstrated that Pluristem's PLX cells can be differentiated into dopaminergic neurons. These neurons were found to have properties favorable to cells, which are known to be helpful in treating PD. These properties include the expression of tyrosine hydroxylase, and the finding of elevated nurr1 mRNA levels. Additionally, these neurons were found to secrete favorable neurotrophic factors such as GDNF, BDNF, IGF-1, and astrocytes markers such as S-100-b, GLUL, and GFAP.
About Parkinson's Disease
PD is a well characterized degenerative neurological disease whose symptoms are felt to be related to damage to dopamine-producing cells in the Central Nervous System (CNS). PD is felt to currently afflict appr oximately four million people in the western world which represents a multi-billion dollar market annually.
Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that "the Company believes PLX cells have the potential to treat Parkinson's Disease (PD); that We intend to pursue further in vitro and in vivo studies with our PLX cells in the treatment of Parkinson's Disease as well as other disorders of the central nervous system. A s a cellular therapy for PD and other neurodegenerative diseases;that our PLX cells could be a readily available source of important enzymes, neurotransmitters and neurotrophic factors. And that Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
Segue Ventures LLC
Craig Bird, 215-885-4981
Investors' Message Board: